Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care-associated infections and review published case reports.
Keywords: carbapenemase; case series; cefiderocol; drug-resistant gram-negatives; review.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.